News | February 02, 2009

Emerging Risk Factors Can be Better Indicators of Heart Disease

February 2, 2009 - A recent study published in Clinical Cardiology revealed that "emerging risk factors," including detailed cholesterol measurements such as HDL(2) and remnant lipoprotein particles, play a much greater role in determining heart disease risk than previously thought, and that traditional risk factors such as age, standard cholesterol levels and blood pressure do a poor job of predicting heart disease risk in younger, healthy adults with a family history of early heart disease.

The study was entitled Prevalence of Emerging Cardiovascular Risk Factors in Younger Individuals with a Family History of Premature Coronary Heart Disease and Low Framingham Risk Score, and is said to be the latest in a series of clinical studies showing that the traditional Framingham risk score doesn't always do a good job of estimating that risk, especially among people in their mid-30s to early 60s.

Measurement of emerging clinical and lipid risk factors in the study was done with the VAP) (Vertical Auto Profile) Cholesterol Test from Atherotech Inc. The VAP Test provides physicians with direct measurement of LDL (bad cholesterol), HDL (good cholesterol) and all relevant cholesterol subclasses. These often overlooked subclasses include non-HDL, particle number as determined by accurate apoB, and emerging risk factors such as Lp(a), low-density lipoprotein remnants and small dense LDL.

The VAP Test, says the company, is also the only commercially available advanced lipid profile that routinely reports all three lipoprotein parameters — LDL, non-HDL and apoB — considered necessary by the 2008 expert consensus guidelines issued by the American Diabetes Association and American College of Cardiology.

In the Clinical Cardiology study, researchers evaluated 89 men and women with an average age of 47 with a family history of premature coronary heart disease (CHD) and who had a low Framingham risk score. The risk factors included in the Framingham calculation are age, total cholesterol, HDL cholesterol, systolic blood pressure, treatment for hypertension and cigarette smoking. Patients with existing CHD or CHD equivalents were excluded.

The most common emerging risk factor for heart disease that was missed using traditional cholesterol testing methods was low HDL(2). The second most overlooked emerging risk factor was high levels of triglyceride rich remnant lipoproteins such as IDL (intermediate density lipoproteins) and very low density lipoproteins (VLDL(3)). Low HDL(2) was present in 72 percent of the study group, and high levels of IDL + VLDL(3) were present in nearly half (49 percent) of patients. In addition, 38 percent of the participants had coronary atherosclerosis as reflected in EBCT derived coronary calcium scores, and 24 percent of the participants had "at-risk" levels of C-reactive protein (above 3 mg/dl).

All patients were screened for emerging clinical and lipid risk factors with the VAP Test. Researchers noted that only 11 percent of the participants would have been prescribed lipid-lowering therapy based on current National Cholesterol Education Program Adult Treatment Panel III guidelines.

The authors concluded that, "The Framingham risk score underestimates cardiovascular risk in individuals with a family history of premature CHD, and screening for emerging cardiovascular risk factors may better assess CV (cardiovascular) risk in these patients."

For more information: www.thevaptest.com

Related Content

Siemens Healthineers to Acquire Epocal from Alere
News | Point of Care Testing | July 26, 2017
Siemens Healthineers has entered into a definitive agreement to acquire Epocal Inc., a subsidiary of Alere Inc. Epocal...
Alere point of care POC testing for INR
News | Point of Care Testing | July 17, 2017 | Dave Fornell
July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is on
Siemens Xprecia Stride anticoagulation, coagulation PT/INR or INR testing at the point of care (POC)

Point-of-care coagulation PT/INR testing with handheld devices can help improve outcomes with more convenient and frequent measurements to keep patients within the therapeutic range of anticoagulant agents.

Feature | Point of Care Testing | May 05, 2017 | Nicholas C. Vanderslice, Ph.D., and Arnol S. Rios
Point-of-care (POC) coagulation analyzers that measure prothrombin time/international normalized ratio (PT/INR) on fi
HyperMed Imaging, HyperView portable tissue oxygenation measurement system, FDA clearance
Technology | Point of Care Testing | January 27, 2017
HyperMed Imaging Inc. announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the...

The Xprecia Stride Coagulation Analyzer delivers fast, reliable prothrombin time/international normalized ratio (PT/INR) testing for point-of-care monitoring and management of oral anticoagulation therapy with warfarin, a vitamin K antagonist. It is the latest INR testing system to enter the market in late 2016. Read the article “Siemens Receives FDA Clearance of Xprecia Stride Coagulation Analyzer.”
 

 

Feature | Point of Care Testing | December 30, 2016 | Ravi Chawat
Point of care testing devices are gaining widespread approval for prompt medical diagnoses, especially in cardiology
INRatio, Alere, Abbott, I and R testing, INR testing
Feature | Point of Care Testing | December 07, 2016
December 7, 2016 — Abbott has filed a complaint to terminate its proposed acquisition of Alere based on the substanti
Siemens, FDA clearance, Xprecia Stride Coagulation Analyzer, point-of-care testing
Technology | Point of Care Testing | November 10, 2016
Siemens Healthineers announced U.S. Food and Drug Administration (FDA) 510(k) clearance for a hand-held portable...
Abbott, Alere, acquisition, point of care diagnostics
News | Point of Care Testing | February 03, 2016
Abbott and Alere Inc. announced a definitive agreement for Abbott to acquire Alere. Under the terms of the agreement,...
News | Point of Care Testing | December 22, 2015
Trinity Biotech plc announced submission of its Meritas Point of Care Analyzer and Meritas cardiac troponin-I (cTnI)...
The Lancet results, Abbott ARCHITECT STAT High Sensitive Troponin-I test, rule out myocardial infarction, Accident and Emergency, A&E
News | Point of Care Testing | October 13, 2015
The Lancet published results online that show Abbott’s ARCHITECT STAT High Sensitive Troponin-I (hsTnl) test may rule...
Overlay Init